In an effort to provide you with timely market feedback from the 2016 ASCO Annual Meeting, OBR and MDoutlook are pleased to share results from MDoutlook’s OncoPolls™ conducted immediately after the meeting. This report explores presentations concerning the treatment of ALK+ non-small cell lung cancer (NSCLC) and the use of checkpoint inhibitors as therapy for small cell lung cancer (SCLC).
- Primary research phase involved a global survey to verified and validated medical oncologists and multi-disciplinary physicians with an identified clinical interest in lung cancers utilizing targeting parameters within the proprietary MDoutlook® global cancer treater panel
- Timing: June 2016. Launched 2 days after close of 2016 American Society of Clinical Oncology (ASCO) Annual Meeting, held in Chicago, IL, June 3-7, 2016
- Fielding to proprietary panel of cancer treaters, targeted by clinical interest
- Data capture via interactive web-based survey instrument, utilizing proven MDoutlook methodology and proprietary technology
- Links to discussed abstracts on the ASCO website were provided within the survey
- Reponses at data collection: 146
- Responses are from 14 countries: Austria, Belgium, Brazil, Canada, France, Germany, Italy, Japan, Poland, Spain, Switzerland, Turkey, United Kingdom and US
- On a 0 – 5 scale of 0 = no awareness to 5 = very aware, clinicians have an above average awareness
- Higher level of awareness was seen by those outside of the US (~3.8 vs. 3.3)
- Much higher level of awareness (nearly a full point) was seen among the attendees compared to those who did not attend (not shown)
- Clinical impact, also rated on a 0 – 5 scale of 0 = no impact at all to 5 = very important, oncologists see this new information as very clinically meaningful, with average rating of ~3.7
- Only small differences in importance was seen between US and Ex-US and between attendees and non-attendees (not shown)
- There is some concern that these results were from a single country (Japan) and thus may not be entirely reproducible to all patients (not shown). Large scale integration of these results into clinical practice may wait until the results of the global ALEX trial are available.
- On the same 0 – 5 scale, there is an above average level awareness about this brigatinib presentation in the US, while awareness outside of the US is well above average
- Much higher level of awareness among the attendees (3.7) compared to those who did not attend (2.2)
- The 2nd generation ALK inhibitor brigatinib is seen as welcome addition to the oncologists’ armamentarium for ALK+ NSCLC, as seen by the clinically important ratings
- The clinical importance averaged ~3.5, regardless of region
- With the higher level of awareness, more importance was seen by the attendees than with the non-attendees (not shown)
- Treaters of SCLC are aware about this new clinical data combining nivolumab (anti-PD-1) with ipilimumab (anti-CTLA-4) with level of awareness of ~3.7
- Very high level of awareness among the attendees (4.1) compared to those who did not attend (3.0); highest level of awareness among these lung cancer abstracts by non-attendees (not shown)
- The use of the dual checkpoint inhibition in SCLC is seen as clinically important
- US oncologists assign slightly more importance to this information, average rating of 4.0 vs. 3.6 for ex-US respondents
- Over 1/4 of respondents rated the importance as a “5” (not shown)
- Even with the higher level of awareness by the attendees, both attendees and non-attendees have similar views as to its importance, upon learning about this new data (not shown)
Conclusions: Immediate Impact of 2016 ASCO Presentations on Clinical Practice for ALK+ NSCLC and SCLC
- All of these studies highlight the importance of the ASCO Annual Meeting to the entire global oncology community – awareness of these presentations are high and can occur quite quickly even for those who did not attend
- The importance of these presentations suggest that integration of these results into clinical practice will happen in relatively short order, especially since most of these agents are already widely available and in use
For a more detailed analysis report, please click here to download the full report.
Submitted by Robert Stephan, VP, Research and Physician Society, and Jan Heybroek, President MDoutlook.